Arixtra and Skin discoloration - bluish - a phase IV clinical study of FDA data

Summary:

Skin discoloration - bluish is reported as a side effect among people who take Arixtra (fondaparinux sodium), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lasix, and have Sedation.

The phase IV clinical study analyzes which people have Skin discoloration - bluish when taking Arixtra. It is created by eHealthMe based on reports of 9,755 people who have side effects when taking Arixtra from the FDA, and is updated regularly.

What is Arixtra?

Arixtra has active ingredients of fondaparinux sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 9,830 Arixtra users. Check the latest studies of Arixtra.

What is Skin discoloration - bluish?

Skin discoloration - bluish (bluish colour of skin) is found to be associated with 1,088 drugs and 2,156 conditions by eHealthMe. Check the latest studies of Skin discoloration - bluish.

On Jul, 17, 2026

9,755 people reported to have side effects when taking Arixtra.
Among them, 22 people (0.23%) have Skin discoloration - bluish.

Could Arixtra cause Skin discoloration - bluish?

Among these 22 people:

How long have people been on Arixtra when they have Skin discoloration - bluish? *

What is the gender of people who have Skin discoloration - bluish when taking Arixtra? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Skin discoloration - bluish when taking Arixtra? *

What are other drugs people take besides Arixtra? *

Lasix: 9 people, 40.91%
Nexium: 8 people, 36.36%
Norepinephrine Bitartrate: 5 people, 22.73%
Atropine Sulfate: 5 people, 22.73%
Atrovent: 5 people, 22.73%
Levothyroxine Sodium: 5 people, 22.73%
Duragesic-100: 5 people, 22.73%
Propofol: 5 people, 22.73%
Pancuronium: 5 people, 22.73%
Heparin: 5 people, 22.73%

What are other side effects people have besides Skin discoloration - bluish? *

Acute Kidney Failure: 8 people, 36.36%
Lactic Acidosis (low ph in body tissues): 6 people, 27.27%
Ards (Acute Respiratory Distress Syndrome) (sudden failure of the respiratory (breathing) system): 5 people, 22.73%
C-Reactive Protein Increased: 5 people, 22.73%
Embolism (obstruction of an artery, typically by a clot of blood or an air bubble): 5 people, 22.73%
Hepatic Failure (liver failure): 5 people, 22.73%
Venous Thrombosis (blood clot (thrombus) that forms within a vein): 5 people, 22.73%
Hydrocephalus (water on the brain): 5 people, 22.73%
Hypotension (abnormally low blood pressure): 5 people, 22.73%
Venous Thrombosis Limb (blood clot that forms in a vein in the limb): 5 people, 22.73%

What are the existing conditions these people have? *

Traumatic Haemorrhage (a bleeding due to trauma): 5 people, 22.73%
Analgesia: 5 people, 22.73%
Catheter Related Infection: 5 people, 22.73%
Sedation: 5 people, 22.73%
Hypovolaemia (a decreased volume of circulating blood in the body): 4 people, 18.18%
Anaesthesia: 4 people, 18.18%
Heart Disease: 4 people, 18.18%
Agitation (state of anxiety or nervous excitement): 4 people, 18.18%
Oedema (fluid collection in tissue): 4 people, 18.18%
Pain: 4 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Arixtra and have Skin discoloration - bluish?

- Check whether Skin discoloration - bluish is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Arixtra:

Arixtra (9,830 reports)

Browse all side effects of Arixtra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin discoloration - bluish:

Skin discoloration - bluish (1,088 drugs)

Browse all the conditions that are associated with Skin discoloration - bluish:

Skin discoloration - bluish (2,156 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fondaparinux sodium (the active ingredients of Arixtra) and Arixtra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.